CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 102470-102734 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T615","span":{"begin":0,"end":264},"obj":"Sentence"},{"id":"T78895","span":{"begin":0,"end":264},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Potential risk factors for increased mortality in patients with RSV pneumonia includes the co-pathogens, concomitant immunosuppression (steroids, anti-lymphocyte antibodies), lymphopenia, preexisting lung disease, and the therapy used, including the time of onset."}

{"project":"Epistemic_Statements","denotations":[{"id":"T259","span":{"begin":0,"end":264},"obj":"Epistemic_statement"}],"text":"Potential risk factors for increased mortality in patients with RSV pneumonia includes the co-pathogens, concomitant immunosuppression (steroids, anti-lymphocyte antibodies), lymphopenia, preexisting lung disease, and the therapy used, including the time of onset."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T20","span":{"begin":0,"end":264},"obj":"Sentence"}],"text":"Potential risk factors for increased mortality in patients with RSV pneumonia includes the co-pathogens, concomitant immunosuppression (steroids, anti-lymphocyte antibodies), lymphopenia, preexisting lung disease, and the therapy used, including the time of onset."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T560","span":{"begin":68,"end":77},"obj":"Disease"},{"id":"T561","span":{"begin":175,"end":186},"obj":"Disease"},{"id":"T562","span":{"begin":200,"end":212},"obj":"Disease"}],"attributes":[{"id":"A560","pred":"mondo_id","subj":"T560","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A561","pred":"mondo_id","subj":"T561","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A562","pred":"mondo_id","subj":"T562","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"}],"text":"Potential risk factors for increased mortality in patients with RSV pneumonia includes the co-pathogens, concomitant immunosuppression (steroids, anti-lymphocyte antibodies), lymphopenia, preexisting lung disease, and the therapy used, including the time of onset."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T141","span":{"begin":68,"end":77},"obj":"Phenotype"},{"id":"T142","span":{"begin":175,"end":186},"obj":"Phenotype"},{"id":"T143","span":{"begin":200,"end":212},"obj":"Phenotype"}],"attributes":[{"id":"A141","pred":"hp_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A142","pred":"hp_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A143","pred":"hp_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/HP_0002088"}],"text":"Potential risk factors for increased mortality in patients with RSV pneumonia includes the co-pathogens, concomitant immunosuppression (steroids, anti-lymphocyte antibodies), lymphopenia, preexisting lung disease, and the therapy used, including the time of onset."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T95","span":{"begin":200,"end":204},"obj":"Body_part"}],"attributes":[{"id":"A95","pred":"uberon_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Potential risk factors for increased mortality in patients with RSV pneumonia includes the co-pathogens, concomitant immunosuppression (steroids, anti-lymphocyte antibodies), lymphopenia, preexisting lung disease, and the therapy used, including the time of onset."}